{"id":568354,"date":"2021-10-11T16:32:01","date_gmt":"2021-10-11T16:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=568354"},"modified":"2021-10-11T16:32:01","modified_gmt":"2021-10-11T16:32:01","slug":"essential-thrombocythemia-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/essential-thrombocythemia-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working_568354.html","title":{"rendered":"Essential Thrombocythemia Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1633938590.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Essential Thrombocythemia Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working\" src=\"https:\/\/www.abnewswire.com\/uploads\/1633938590.png\" alt=\"Essential Thrombocythemia Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Essential Thrombocythemia (ET)-Market Insights, Epidemiology, and Market Forecast\u20132030\u2019 report deliver an in-depth understanding of the Essential Thrombocythemia (ET), historical and forecasted epidemiology as well as the Essential Thrombocythemia (ET) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight has launched a new report on <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/essential-thrombocythemia-et-market-insights?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&#8220;Essential Thrombocythemia &#8211; Market Insights, Epidemiology, and Market Forecast-2030&rdquo;.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s<strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/essential-thrombocythemia-et-market-insights?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;Essential Thrombocythemia &ndash; Market Insights, Epidemiology, and Market Forecast-2030&Prime;<\/a><\/strong> report delivers an in-depth understanding of the Essential Thrombocythemia, historical and forecasted epidemiology as well as the Essential Thrombocythemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/4f32669618e0a5b0029da19d4c59e5d9.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key facts of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/essential-thrombocythemia-et-market-insights?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Essential Thrombocythemia Market Report<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per DelveInsight analysts, the total prevalent population of Essential Thrombocythemia in the 7MM was 240,774 in 2020.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The estimates show the highest prevalence of Essential Thrombocythemia in the United States with 149,157 cases.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Estimates observed that the age group 60-80 years accounted for the highest cases of Essential Thrombocythemia in the United States.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In 2020, the prevalent population of Essential Thrombocythemia in Germany was found to be 19,530.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key benefits of the report:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Essential Thrombocythemia market report covers a descriptive overview and comprehensive insight of the Essential Thrombocythemia Epidemiology and Essential Thrombocythemia&nbsp; market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Essential Thrombocythemia market report provides insights on the current and emerging therapies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Essential Thrombocythemia market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Essential Thrombocythemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Essential Thrombocythemia market.<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Got queries? <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/essential-thrombocythemia-et-market-insights?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Click here to know more about the Essential Thrombocythemia Market Landscape.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Essential Thrombocythemia Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Essential Thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by an increased number of platelets in the blood (MPN Research Foundation, n.d.). The overproduction (megakaryocytic hyperplasia) of platelet-forming cells, called &ldquo;megakaryocytes,&rdquo; in the marrow results in the release of too many platelets into the blood.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Essential Thrombocythemia Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The dynamics of the Essential Thrombocythemia market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as PharmaEssentia, Novartis, Imago BioSciences, Geron Corporation, and others during the forecasted period 2018-2030.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more by requesting for sample <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/essential-thrombocythemia-et-market-insights?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Essential Thrombocythemia Market Landscape&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Essential Thrombocythemia Pipeline Therapies and Key Companies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ropeginterferon alfa-2b\/P1101: PharmaEssentia<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ruxolitinib: Novartis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">IMG-7289\/Bomedemstat: Imago BioSciences<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Imetelstat: Geron Corporation&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And others<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Essential Thrombocythemia Market Drivers&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rich emerging pipeline<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Updated diagnostic criteria<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Reach of bone marrow biopsy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Research and Development<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Essential Thrombocythemia Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Essential Thrombocythemia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Essential Thrombocythemia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Essential Thrombocythemia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Country-Specific Patient Population of Essential Thrombocythemia&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Essential Thrombocythemia Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Essential Thrombocythemia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Essential Thrombocythemia Market Outlook<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Country-Wise Essential Thrombocythemia Market Analysis (2018&ndash;2030)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Essential Thrombocythemia Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=essential-thrombocythemia-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=essential-thrombocythemia-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Essential Thrombocythemia (ET)-Market Insights, Epidemiology, and Market Forecast\u20132030\u2019 report deliver an in-depth understanding of the Essential Thrombocythemia (ET), historical and forecasted epidemiology as well as the Essential Thrombocythemia (ET) market trends in the United States, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/essential-thrombocythemia-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working_568354.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-568354","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=568354"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568354\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=568354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=568354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=568354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}